Stockreport

Lexicon Pharmaceuticals and Ipsen Biopharmaceuticals Canada Inc. Announce Health Canada Approval of XERMELO® (Telotristat Ethyl) for the Treatment of Refractory Carcinoid Syndrome Diarrhea...

Lexicon Pharmaceuticals, Inc.  (LXRX) 
Last lexicon pharmaceuticals, inc. earnings: 4/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: lexpharma.com/investors
PDF Approval Enables Availability of First-in-Class Oral Tryptophan Hydroxylase Inhibitor that Sustains Improvement of Carcinoid Syndrome Diarrhea in Adults Inadequately Con [Read more]